Mal-Val-Lys-PAB-MMAE TFA is a drug-linker conjugate for ADC. Mal-Val-Lys-PAB-MMAE TFA consists of a Tubulin inhibitor (MMAE) and a linker (Mal-Val-Lys-PAB). Mal-Val-Lys-PAB-MMAE TFA can be used for synthesis of ADCs [1].
In Vitro, ADC consists of an antibody, to which ADC cytotoxins are linked via ADC linkers[1].
References:
[1]. Chen T Z, et al. Novel hydrophilic glycosylation linker, synthesis and application thereof. CN115429889A. 2022-12-06.
In Vitro, ADC consists of an antibody, to which ADC cytotoxins are linked via ADC linkers[1].
References:
[1]. Chen T Z, et al. Novel hydrophilic glycosylation linker, synthesis and application thereof. CN115429889A. 2022-12-06.
















